FDA Should Look Through IIRIS To Improve Science, Panel Says; Funding Is Worry
Increasing developments in emerging sciences, such as personalized medicine, could reach roadblocks at FDA where limited resources for specialized personnel and advanced equipment may inhibit research, a report from FDA's Science Board's Subcommittee on Science and Technology shows
You may also be interested in...
21st Century Cures criticized by FDA advisors for unfunded mandates, but legislation also represents best near-term prospect for reforms of the kind the report envisions.
Medical countermeasures expert Luciana Borio moves to chief scientist role; Hamburg offers preview of the leadership approaches of Stephen Ostroff and Robert Califf.
A report on the state of FDA’s workforce finds that eight of 10 medical offices are temporary or term appointed and that it takes about six months to bring a new employee onboard. FDA’s new Office of Human Resources is seeking to reduce the time-to-hire.